Homology Modeling, Structural Validation, Active Site Identification, and Binding Pocket Analysis of Leishmania major Spermidine Synthase, An in Silico Structural Characterization Study
Main Article Content
Abstract
Background: Leishmaniasis remains a major global health challenge due to limited therapeutic options and emerging drug resistance. Leishmania major spermidine synthase (SPDS) is an essential enzyme in polyamine biosynthesis, serving as a critical precursor for the trypanothione antioxidant system. Despite its importance for parasite viability and its absence in human hosts, the three-dimensional architecture of L. major SPDS remains experimentally unresolved. Structural characterization is therefore imperative to facilitate the rational design of selective inhibitors targeting this vital metabolic pathway.
Methods: The tertiary structure was predicted via homology modeling using the SWISS-MODEL server and validated through ERRAT, PROCHECK, and Verify3D analysis. Conserved domains were identified using NCBI CD-Search. Binding pockets were characterized via PrankWeb and DoGSiteScorer while potential active site residues were determined through structural comparison with ligand-associated homologous templates and UniProt-annotated catalytic information.
Results: The generated model, based on a Trypanosoma cruzi template (67.92% identity), demonstrated high reliability with a GMQE score of 0.87 and an ERRAT factor of 91.034%. Ramachandran plot analysis showed 99.0% of residues in acceptable regions. Pocket 1 was identified as the primary druggable site, exhibiting a volume of 931.34 ų and a drug score of 0.83. Eleven conserved binding pocket-associated residues and the UniProt-annotated catalytic residue Asp173 were identified within the active region.
Conclusion: This study establishes a high-quality structural framework for L. major spermidine synthase. The identified binding pockets and conserved active-site residues provide essential molecular insights for future virtual screening and structure-based drug discovery efforts aimed at developing potent and selective anti-leishmanial therapeutics.
Article Details
References
1. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–70.
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
3. World Health Organization. Leishmaniasis [Inter-net]. World Health Organization; 2023 Jan 12 [cited 2026 Nov 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
4. Reguera RM, Pérez-Pertejo Y, Gutiérrez-Corbo C, Domínguez-Asenjo B, Ordóñez C, García-Estrada C, et al. Current and promising novel drug candi-dates against visceral leishmaniasis. Pure Appl Chem. 2019;91(8):1385–404.
5. Dufe VT, Ingner D, Heby O, Khomutov AR, Persson L, Al-Karadaghi S. A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. Biochem J. 2007;405(2):261–8.
6. Singh S, Sarma S, Katiyar SP, Das M, Bhardwaj R, Sundar D, et al. Probing the molecular mechanism of hypericin-induced parasite death provides insight into the role of spermidine beyond redox metabo-lism in Leishmania donovani. Antimicrob Agents Chemother. 2015;59(1):15–24.
7. Melcon-Fernandez E, Galli G, García-Estrada C, Balaña-Fouce R, Reguera RM, Pérez-Pertejo Y. Miltefosine and nifuratel combination: a promising therapy for the treatment of Leishmania donovani visceral leishmaniasis. Int J Mol Sci. 2023;24(2):1635.
8. Roberts SC, Jiang Y, Gasteier J, Frydman B, Mar-ton LJ, Heby O, et al. Leishmania donovani polyam-ine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyam-ine analogs. Antimicrob Agents Chemother. 2007;51(2):438–45.
9. Hubin TJ, Walker AN, Davilla DJ, Carder Freeman TN, Epley BM, Hasley TR, et al. Tetraazamacrocy-clic derivatives and their metal complexes as an-tileishmanial leads. Polyhedron. 2019;163:42–53.
10. Wadanambi P. Computational approach to identify potential antileishmanial activity of reported inhibi-tor, E5700 and two natural alkaloids against Leish-mania donovani Squalene Synthase. Exp Results. 2020;1:e31.
11. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111–26.
12. Sundar S, Singh A. Recent developments and fu-ture prospects in the treatment of visceral leishman-iasis. Ther Adv Infect Dis. 2016;3(3–4):98–109.
13. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat. 2004;7(4–5):257–66.
14. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol. 1992;46:695–729.
15. Müller S, Liebau E, Walter RD, Krauth-Siegel RL. Thiol-based redox metabolism of protozoan para-sites. Trends Parasitol. 2003;19(7):320–8.
16. Tabor CW, Tabor H. Polyamines. Annu Rev Bio-chem. 1984;53:749–90.
17. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–94.
18. Roberts SC, Jiang Y, Jardim A, Carter NS, Heby O, Ullman B. Genetic analysis of spermidine synthase from Leishmania donovani. Mol Biochem Parasitol. 2001;115(2):217–26.
19. Ilari A, Fiorillo A, Baiocco P, Poser E, Angiulli G, Colotti G. Targeting polyamine metabolism for finding new drugs against leishmaniasis: a review. Mini Rev Med Chem. 2015;15(3):243–52.
20. Heby O, Roberts SC, Ullman B. Polyamine biosyn-thetic enzymes as drug targets in parasitic protozoa. Biochem Soc Trans. 2003;31(2):415–9.
21. Boitz JM, Yates PA, Kline C, Gaur U, Wilson ME, Ullman B, et al. Leishmania donovani ornithine de-carboxylase is indispensable for parasite survival in the mammalian host. Infect Immun. 2009;77(2):756–63.
22. Willert EK, Phillips MA. Regulated expression of an essential allosteric activator of polyamine biosyn-thesis in African trypanosomes. PLoS Pathog. 2008;4(10):e1000183.
23. Carter NS, Kawasaki Y, Nahata SS, Elikaee S, Ra-jab S, Salam L, et al. Polyamine metabolism in Leishmania parasites: a promising therapeutic tar-get. Med Sci (Basel). 2022;10(2):24.
24. Gilroy C, Olenyik T, Roberts SC, Ullman B. Sper-midine synthase is required for virulence of Leish-mania donovani. Infect Immun. 2011;79(7):2764–9.
25. Birkholtz LM, Williams M, Niemand J, Louw AI, Persson L, Heby O. Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities. Biochem J. 2011;438(2):229–44.
26. Roberts SC, Scott J, Gasteier JE, Jiang Y, Brooks B, Jardim A, et al. S-adenosylmethionine decarbox-ylase from Leishmania donovani. Molecular, genet-ic, and biochemical characterization of null mutants and overproducers. J Biol Chem. 2002;277(8):5902–9.
27. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. To-towa: Humana Press; 2005. p. 571–607.
28. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292(2):195–202.
29. Geourjon C, Deléage G. SOPMA: significant im-provements in protein secondary structure predic-tion by consensus prediction from multiple align-ments. Comput Appl Biosci. 1995;11(6):681–4.
30. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7:539.
31. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16(4):404–5.
32. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996;266:540–53.
33. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–303.
34. Colovos C, Yeates TO. Verification of protein struc-tures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511–9.
35. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283–91.
36. Haqmal, A., Momand, Z. K., & Aftab, S. (2026). Structural modeling of Luciferin 4-Monooxygenase from Human Respiratory Syncytial Virus using homology techniques. Spinghar Journal of Biomed-ical Science, 2(1), 80–95. https://doi.org/10.64444/sjbs.21.
37. Benkert P, Biasini M, Schwede T. Toward the es-timation of the absolute quality of individual pro-tein structure models. Bioinformatics. 2011;27(3):343–50.
38. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI's con-served domain database. Nucleic Acids Res. 2015;43(D1):D222–6.
39. Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: computed atlas of surface topography of pro-teins. Nucleic Acids Res. 2018;46(W1):W363–7.
40. Amano Y, Namatame I, Tateishi Y, Honboh K, Tanabe E, Niimi T, et al. Structural insights into the novel inhibition mechanism of Trypanosoma cruzi spermidine synthase. Acta Crystallogr D Biol Crystallogr. 2015;71:1879–89.
41. Volkamer A, Kuhn D, Rippmann F, Rarey M. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assess-ment. Bioinformatics. 2012;28(15):2074–5.
42. Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res. 2019;47(W1):W345–9.
43. Sarma M, Borkotoky S, Dubey VK. Structure-based drug designing against Leishmania donovani using docking and molecular dynamics simulation studies: exploring glutathione synthetase as a drug target. J Biomol Struct Dyn. 2024;42(14):7628–36.
44. Vidhya VM, Dubey VK, Ponnuraj K. Identification of two natural compound inhibitors of Leishmania donovani spermidine synthase (SpdS) through mo-lecular docking and dynamic studies. J Biomol Struct Dyn. 2018;36(10):2678–93.
45. Khare P, Gupta AK, Gajula PK, Sunkari KY, Jaiswal AK, Das S, et al. Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. J Chem Inf Model. 2012;52(3):777–91.
46. Sakyi PO, Broni E, Amewu RK, Miller WA III, Wilson MD, Kwofie SK. Homology modeling, de novo design of ligands, and molecular docking identify potential inhibitors of Leishmania donovani 24-sterol methyltransferase. Front Cell Infect Mi-crobiol. 2022;12:859981.
47. Sheikh SY, Ansari WA, Hassan F, Faruqui T, Khan MF, Akhter Y, et al. Drug repositioning to discover novel ornithine decarboxylase inhibitors against visceral leishmaniasis. J Mol Recognit. 2023;36(7):e3021.
48. Kar RK, Ansari MY, Suryadevara P, Sahoo BR, Sahoo GC, Dikhit MR, et al. Computational eluci-dation of structural basis for ligand binding with Leishmania donovani adenosine kinase. Biomed Res Int. 2013;2013:609289.
49. Sakyi PO, Kwofie SK, Tuekpe JK, Gwira TM, Bro-ni E, Miller WA III, et al. Inhibiting Leishmania do-novani sterol methyltransferase to identify lead compounds using molecular modelling. Pharma-ceuticals (Basel). 2023;16(3):330.
50. Vadloori B, Sharath AK, Prabhu NP, Maurya R. Homology modelling, molecular docking, and mo-lecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A. BMC Res Notes. 2018;11:246.
51. Viana JO, Weber KC, da Cruz LEG, Santos RO, Rocha GB, Jordão AK, et al. In silico structural in-sights and potential inhibitor identification based on the benzothiazole core for targeting L. major pteri-dine reductase 1. ACS Omega. 2025;10(1):306–17.
52. Rajasekaran R, Chen YPP. Probing the structure of L. major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads. J Mol Model. 2012;18:4089–100.
53. Challapa-Mamani MR, Tomás-Alvarado E, Espino-za-Baigorria A, León-Figueroa DA, Sah R, Rodri-guez-Morales AJ, et al. Molecular docking and mo-lecular dynamics simulations in related to Leishma-nia donovani: an update and literature review. Trop Med Infect Dis. 2023;8(10):457.
54. Shakoori AM, Alhakami F, Sindi G, Alyahyawi AY, Alhazzaa RA. Molecular docking of dauno-rubicin and etoposide drugs against Leishmania do-novani: a theoretical study. J Vector Borne Dis. 2024;61(3):369–75.
55. Singh S, Prajapati VK. Exploring actinomycetes natural products to identify potential multi-target inhibitors against Leishmania donovani. 3 Biotech. 2022;12(9):235.
56. Bora K, Sarma M, Kanaujia SP, Dubey VK. Dual-target drugs against Leishmania donovani for poten-tial novel therapeutics. Sci Rep. 2023; 13:18363.
57. Wadanambi PM, Mannapperuma U. Computa-tional study to discover potent phytochemical in-hibitors against drug target, squalene synthase from Leishmania donovani. Heliyon. 2021;7(6):e07178.
58. Arthur MN, Hanson G, Broni E, Sakyi PO, Men-sah-Brown H, Miller WA III, et al. Natural product identification and molecular docking studies of L. major pteridine reductase inhibitors. Pharmaceuti-cals (Basel). 2025;18(1):6.
59. Mansuri R, Diwan A, Mundotiya PK, Singh J. Structural analysis and in-silico inhibitor interaction studies of Leishmania donovani heat-shocked pro-teins 83 (HSP83). Int J Life Sci Pharma Res. 2023;13(Suppl 1):P8–18.
60. Arya PK, Barik K, Kumar A. Targeting spermidine synthase in Leishmania donovani: molecular dock-ing and molecular dynamics simulation-based eval-uation of Indian medicinal plant phytochemicals. In Silico Pharmacol. 2026;14(1):12.